Healthy Clinical Trial
Official title:
A Phase I Bridging Study to Evaluate the PK, PD, Safety and Tolerability of SR1375 in Healthy Subjects
Verified date | December 2022 |
Source | Shanghai SIMR Biotechnology Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind, placebo-controlled phase I bridging study to evaluate the PK, PD, safety and tolerability of SR1375 in healthy subjects.
Status | Completed |
Enrollment | 32 |
Est. completion date | October 5, 2022 |
Est. primary completion date | October 5, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Healthy males and females who are 18 to 45 years of age. 2. Based on medical history, physical examination, laboratory examination, chest CT scan, abdominal B-ultrasound, vital signs and ECG, the investigator considered that the results were normal or abnormal but no clinical significance. 3. Bodyweight of male > 50 kg, Bodyweight of female > 45 kg and body mass index (BMI) between 18 and 28 kg/m2. 4. Male subjects must agree to use a highly effective contraceptive method from signing the consent form until at least 90 days after the last dose of study drug, and must be willing not to donate sperm. 5. Healthy female volunteers must be: i. Of non-childbearing potential(with a documented tubal ligation, bilateral salpingectomy, hysterectomy, or menopause for more than 1 year) ii. Of childbearing potential, must have a negative pregnancy test at the screening visit (blood test), must agree to use a highly effective contraceptive method from signing the consent form until at least 30 days after the last dose of study drug. 6. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Exclusion Criteria: 1. History of hypercoagulable state or history of thrombosis. 2. Current or chronic history of liver disease or known hepatic or biliary abnormalities. 3. History of sensitivity to any of the investigational medicinal products (IMPs), or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation. 4. History of asthma (excluding resolved childhood asthma), severe allergic responses. 5. History of significant drug abuse within one year of screening. 6. Except for topical (no significant systemic exposure) permitted, use of the following combination agents will be excluded: 1. Use of prescription drugs within 14 days prior to initial administration, or within 7 days or five half-lives of the medication (whichever is longer) prior to the first study drug administration, except occasional use of paracetamol (up to a maximum of 2000 mg per day of paracetamol and per local or national abelling). 2. Use the health supplement 7 days or 5 half-life before the first administration of the investigational drug. 3. Use of depot injection or subcutaneous implantation drugs within 3 months prior to the first study drug administration. 4. Received vaccine within 1 month prior to the first administration of the investigational drug. 7. A positive Hepatitis B surface antigen, positive Hepatitis C antibody and positive test for human immunodeficiency virus (HIV) antibody or treponema pallidum antibody. 8. A positive drug/alcohol result. 9. History of regular alcohol consumption within 6 months of screening defined as: an average weekly intake of >14 units (1 unit of alcohol ˜360 mL beer or 45 mL 40% alcohol spirits or 150 mL wine), or abstain from alcohol during the study. 10. Within 6 months of screening, smoking more than 5 cigarettes(including e- cigarettes). 11. Donation or lost in excess of 400 mL of blood within 2 months of Day 1 or donation of plasma within 14 days of Day 1. 12. The subject has participated in a clinical trial within 3 months of receiving IMP. 13. Unable to refrain from consumption of Seville oranges, grapefruit or grapefruit juice within 24h prior to the first dose of IMP until the Safety Follow-up visit. 14. Breast-feeding and/or lactating subject. 15. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study. |
Country | Name | City | State |
---|---|---|---|
China | Phase I clinical laboratory of Huashan Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai SIMRD Biotechnology Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cmax | Peak plasma concentration | On scheduled intervals from Day 1 up to Day 54 | |
Primary | Tmax | Time of peak plasma concentration | On scheduled intervals from Day 1 up to Day 54 | |
Primary | AUC | Area under the plasma concentration-time curve | On scheduled intervals from Day 1 up to Day 54 | |
Primary | CL/F | Apparent oral clearance | On scheduled intervals from Day 1 up to Day 54 | |
Primary | t1/2 | Terminal half-life | On scheduled intervals from Day 1 up to Day 54 | |
Primary | Rac | Accumulation ratio | On scheduled intervals from Day 1 up to Day 54 | |
Secondary | The frequency and severity of AEs in healthy volunteers administrated with single and repeated oral doses of SR1375 capsules | AE: Adverse Event | On scheduled intervals from Day 1 up to Day 54 | |
Secondary | PAF-AH | Platelet activating factor acetylhydrolase | On scheduled intervals from Day 1 up to Day 54 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |